vs

Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and Red Violet, Inc. (RDVT). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $23.4M, roughly 1.6× Red Violet, Inc.). On growth, Red Violet, Inc. posted the faster year-over-year revenue change (19.6% vs -57.1%). Over the past eight quarters, Red Violet, Inc.'s revenue compounded faster (15.6% CAGR vs -46.5%).

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

Red Violet, Inc. is a technology firm specializing in advanced data analytics, risk mitigation, and identity verification solutions. It serves clients across law enforcement, financial services, insurance, and corporate compliance sectors, delivering actionable insights from curated public and proprietary data sets to support informed decision-making.

ORGO vs RDVT — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.6× larger
ORGO
$37.2M
$23.4M
RDVT
Growing faster (revenue YoY)
RDVT
RDVT
+76.6% gap
RDVT
19.6%
-57.1%
ORGO
Faster 2-yr revenue CAGR
RDVT
RDVT
Annualised
RDVT
15.6%
-46.5%
ORGO

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ORGO
ORGO
RDVT
RDVT
Revenue
$37.2M
$23.4M
Net Profit
$2.8M
Gross Margin
30.8%
Operating Margin
-185.1%
6.8%
Net Margin
12.0%
Revenue YoY
-57.1%
19.6%
Net Profit YoY
226.2%
EPS (diluted)
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORGO
ORGO
RDVT
RDVT
Q1 26
$37.2M
Q4 25
$225.6M
$23.4M
Q3 25
$150.9M
$23.1M
Q2 25
$101.0M
$21.8M
Q1 25
$86.7M
$22.0M
Q4 24
$126.7M
$19.6M
Q3 24
$115.2M
$19.1M
Q2 24
$130.2M
$19.1M
Net Profit
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
$43.7M
$2.8M
Q3 25
$21.6M
$4.2M
Q2 25
$-9.4M
$2.7M
Q1 25
$-18.8M
$3.4M
Q4 24
$7.7M
$863.0K
Q3 24
$12.3M
$1.7M
Q2 24
$-17.0M
$2.6M
Gross Margin
ORGO
ORGO
RDVT
RDVT
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ORGO
ORGO
RDVT
RDVT
Q1 26
-185.1%
Q4 25
28.1%
6.8%
Q3 25
13.7%
19.8%
Q2 25
-12.5%
12.6%
Q1 25
-30.9%
19.1%
Q4 24
8.1%
1.9%
Q3 24
5.4%
13.1%
Q2 24
-10.7%
16.1%
Net Margin
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
19.4%
12.0%
Q3 25
14.3%
18.3%
Q2 25
-9.3%
12.3%
Q1 25
-21.7%
15.6%
Q4 24
6.1%
4.4%
Q3 24
10.7%
9.0%
Q2 24
-13.1%
13.8%
EPS (diluted)
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
$0.31
$0.20
Q3 25
$0.11
$0.29
Q2 25
$-0.10
$0.18
Q1 25
$-0.17
$0.24
Q4 24
$0.05
$0.06
Q3 24
$0.09
$0.12
Q2 24
$-0.13
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORGO
ORGO
RDVT
RDVT
Cash + ST InvestmentsLiquidity on hand
$91.4M
$43.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$100.9M
Total Assets
$520.0M
$112.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORGO
ORGO
RDVT
RDVT
Q1 26
$91.4M
Q4 25
$93.7M
$43.6M
Q3 25
$63.7M
$45.4M
Q2 25
$73.1M
$38.8M
Q1 25
$110.0M
$34.6M
Q4 24
$135.6M
$36.5M
Q3 24
$94.3M
$35.7M
Q2 24
$89.9M
$30.9M
Total Debt
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
$300.1M
$100.9M
Q3 25
$255.1M
$101.7M
Q2 25
$233.2M
$96.2M
Q1 25
$242.9M
$91.8M
Q4 24
$262.9M
$86.6M
Q3 24
$278.5M
$91.7M
Q2 24
$263.5M
$88.0M
Total Assets
ORGO
ORGO
RDVT
RDVT
Q1 26
$520.0M
Q4 25
$598.7M
$112.0M
Q3 25
$509.8M
$112.1M
Q2 25
$461.1M
$104.8M
Q1 25
$467.4M
$99.1M
Q4 24
$497.9M
$98.5M
Q3 24
$446.3M
$98.0M
Q2 24
$443.2M
$93.5M
Debt / Equity
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORGO
ORGO
RDVT
RDVT
Operating Cash FlowLast quarter
$6.7M
Free Cash FlowOCF − Capex
$6.6M
FCF MarginFCF / Revenue
28.1%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
2.38×
TTM Free Cash FlowTrailing 4 quarters
$28.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
$39.4M
$6.7M
Q3 25
$3.1M
$10.2M
Q2 25
$-32.9M
$7.5M
Q1 25
$-19.9M
$5.0M
Q4 24
$10.9M
$6.7M
Q3 24
$8.7M
$7.2M
Q2 24
$4.7M
$5.7M
Free Cash Flow
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
$34.8M
$6.6M
Q3 25
$844.0K
$10.0M
Q2 25
$-36.5M
$7.3M
Q1 25
$-23.6M
$5.0M
Q4 24
$7.6M
$6.7M
Q3 24
$6.1M
$7.2M
Q2 24
$2.9M
$5.7M
FCF Margin
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
15.4%
28.1%
Q3 25
0.6%
43.3%
Q2 25
-36.1%
33.5%
Q1 25
-27.2%
22.5%
Q4 24
6.0%
34.1%
Q3 24
5.3%
37.8%
Q2 24
2.2%
29.7%
Capex Intensity
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
2.1%
0.5%
Q3 25
1.5%
0.8%
Q2 25
3.6%
0.9%
Q1 25
4.2%
0.2%
Q4 24
2.7%
0.1%
Q3 24
2.2%
0.2%
Q2 24
1.4%
0.3%
Cash Conversion
ORGO
ORGO
RDVT
RDVT
Q1 26
Q4 25
0.90×
2.38×
Q3 25
0.14×
2.41×
Q2 25
2.79×
Q1 25
1.45×
Q4 24
1.43×
7.75×
Q3 24
0.71×
4.22×
Q2 24
2.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons